Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 10, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Xilio Therapeutics, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol XLO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and stockholder voting outcomes rather than financial performance data.
Material Changes and Corporate Actions
- Board Rebalancing: Following his re-election as a Class II director, Daniel Curran, M.D., resigned from that position and was immediately re-appointed as a Class III director. This action was taken to achieve an equal balance of three directors in each of the three board classes. No compensation changes resulted from this transition.
- Director Elections: Stockholders elected Akintunde Bello, Ph.D., Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors for three-year terms expiring in 2029. All nominees received significant majority support.
- Stock Incentive Plan Amendment: Stockholders approved the Amended and Restated 2021 Stock Incentive Plan. The amendment modifies the calculation of the annual evergreen increase to include shares underlying outstanding prefunded warrants.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results Summary
| Matter | Votes For | Votes Against/Withheld | Abstentions |
|---|---|---|---|
| Election of Class II Directors (Avg.) | ~3.7M | ~65K - 130K | N/A |
| Ratification of Auditor | 5,047,290 | 11,876 | 2,957 |
| Amended 2021 Stock Incentive Plan | 3,424,710 | 355,015 | 2,727 |
Outlook, Risks, and Contingencies
The filing does not contain specific management commentary on future financial guidance, operational risks, or contingencies beyond the standard incorporation of the Proxy Statement for details on the Stock Incentive Plan.
Key Facts for Investor Verification
- Verify the impact of the Stock Incentive Plan amendment on future share dilution, specifically regarding the inclusion of prefunded warrants in the evergreen increase calculation.
- Confirm the composition of the Board of Directors following the reclassification of Dr. Curran to Class III.
- Review the full text of the Amended and Restated 2021 Plan (Exhibit 99.1) for specific terms regarding share availability and vesting.
- Note that no financial performance data is disclosed in this specific filing; refer to the most recent 10-K or 10-Q for financial metrics.